Design Therapeutics, Inc. (DSGN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$9.67-9.03%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · DSGN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | — | — | — | 0.2 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 61.1 | 59.1 | 44.4 | 57.1 | 48.6 | 24.8 | 6.1 |
| Operating Income | (82.3) | (79.5) | (62.4) | (78.2) | (67.6) | (35.8) | (8.3) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 8.2 | 9.7 | 12.8 | 11.3 | — | — | — |
| Net Income | |||||||
| Net Income | (74.1) | (69.8) | (49.6) | (66.9) | (63.3) | (35.5) | (8.3) |
| Per Share | |||||||
| Basic EPS | (1.18) | (1.22) | (0.88) | (1.19) | (1.14) | (0.77) | — |
| Diluted EPS | (1.18) | (1.22) | (0.88) | (1.19) | (1.14) | (0.77) | — |
| Basic Weighted Avg Shares | 63.0 | 57.3 | 56.6 | 56.0 | 55.7 | 45.9 | — |
| Diluted Weighted Avg Shares | 63.0 | 57.3 | 56.6 | 56.0 | 55.7 | 45.9 | — |
| Supplemental | |||||||
| EBIT | (82.3) | (79.5) | (62.4) | (78.2) | (67.6) | (35.8) | (8.3) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.